Liver disease is on the rise due to a diversity of causes. Although there are treatments for most of them, there is much investigation to be done to improve lives of those with liver diseases. As a tertiary liver centre we have a responsibility to advance this research and to train the next generation of hepatologists.
Dr. Vincent Bain graduated from medicine in 1981 with a first-class standing. He completed his residency in internal medicine and fellowship in gastroenterology at the University of Alberta Hospital. He then took up an MRC research fellowship at Kings College Hospital in London, England and, in 1989, was recruited to the University of Alberta.
Dr. Bain is medical director of the Liver Transplant Program which is a major referral centre for patients with hepatobiliary diseases. The U of A Liver Transplant Program’s team performs 70 to 90 liver transplants annually and has performed over 1800 since program inception in 1989.
Leadership and Collaborations
Dr. Bain is co-founder of the University of Alberta’s Liver Transplant Program. He was director of the University of Alberta Liver Unit until 2019. He is a former president of the Canadian Association for the Study of Liver Disease and in 2012 received their Distinguished Service Award. In 2015, he was awarded the Prix d’excellence—Specialist of the Year from the Royal College of Physicians and Surgeons of Canada.
Dr. Bain provides clinical supervision for medical students as well as for GIM and GI core residents. He also supervises fellows from the Advanced Hepatology Program. This includes clinical training and supervision of clinical research projects.
antibody mediated rejection-liver, biliary diseases, chronic hepatitis, liver transplantation, polycystic liver disease
Dr. Bain has research interests in viral hepatitis, biliary diseases and liver transplantation including immunosuppression regimes and rejection.
1. Tandon P, Abraldes J, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, Bain VG, Ma M.
Risk of Bacterial Infection in Patients with Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics. Clinical Gastroenterology and Hepatology, 13(6):1189-1196, 2015.
2. Cantarovich, M, Blydt-Hansen, T, Gill, J, Tinckam K, Schiff J, Alwayn I, Bain V, Dipchand A, Isaac S, Kim J, Lien D, Zaltzman J, Young K, Nickerson P. Canadian Forum on Combined Organ Transplantation. Transplantation, 100 (6): 1339-48, 2016
3. Burak K, Meeberg G, Myers R, Fick G, Swain M, Bain VG, Kneteman N, Hilsden R. Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada. Canadian Journal of Gastroenterology, 307 (2), 2016
4. Kao D, Roach B, Park H, Hotte N, Madsen K, Bain V, Tandon P. Fecal Microbiota Transplantation in the Management of Hepatic Encephalopathy. Hepatology, 63 (1): 339-340, 2016
5. Bhanji RA, Ma M, Bain VG, Montano-Loza AJ. Hyperhomocyteinemia is Associated with Cirrhosis Severity and Negative Impact After Liver Transplantation. Liver International, 36(5): 696-704, 2016
6. Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using Rb PET/CT. Journal of Nuclear Cardiology (in press).
7. HCV eradication with direct-acting antivirals does not impact HCC progression on the waiting list or HCC recurrence after liver transplantation. Canadian Journal of Gastroenterology and Hepatology (in press).
Dr. Bain cares for patients with liver disease and performs ERCPs at the University of Alberta Hospital and through the Liver Transplant Program.